Piper Sandler raised the firm’s price target on Edwards Lifesciences (EW) to $90 from $83 and keeps an Overweight rating on the shares. The firm notes the company reported strong Q2 results posting a top- and bottom-line beat. Piper was pleased to see the FY2025 TAVR growth guidance increased to +6%-7% year-over-year, and believes this speaks to a handful of tailwinds at the back of this business.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences Announces Leadership Change in TAVR Division
- Strong Growth Potential for Edwards Lifesciences: Buy Rating Affirmed by Analyst Brandon Vazquez
- Edwards Lifesciences Reports Strong Q2 Growth
- Edwards Lifesciences: Strong Performance Yet Limited Upside Justifies Hold Rating
- Closing Bell Movers: Intel slides after quarterly report